Michael Spellman

Dr. Michael Spellman is Head of Preclinical Development of Hunterian Medicine. He has over thirty years of drug development experience and has been an independent consultant since 2008. Dr. Spellman served as Senior Vice President of Pharmaceutical Development at Dynogen Pharmaceuticals from 2002 to 2008. He was previously Vice President of Quality and Vice President of Process Development at Millennium Pharmaceuticals, and Vice President of Preclinical Development at Coulter Pharmaceuticals. From 1984 to 1998, Dr. Spellman was employed at Genentech, where he led groups in analytical development and product characterization and then served as Director of Pharmacokinetics and Metabolism. Dr. Spellman received his bachelor’s degree from Assumption College and his Ph.D. in Biochemistry from Michigan State University, and performed postdoctoral research in the Department of Organic Chemistry at Stockholm University.